Infective endocarditis after transcatheter aortic valve implantation: results from a large multicenter registry.

BACKGROUND: We aimed to determine the incidence, predictors, clinical characteristics, management, and outcomes of infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). METHODS AND RESULTS: This multicenter registry included 53 patients (mean age, 79±8 years; men, 57%) who suffered IE after TAVI of 7944 patients after a mean follow-up of 1.1±1.2 years (incidence, 0.67%, 0.50% within the first year after TAVI). Mean time from TAVI was 6 months (interquartile range, 1-14 months). Orotracheal intubation (hazard ratio, 3.87; 95% confidence interval, 1.55-9.64; P=0.004) and the self-expandable CoreValve system (hazard ratio, 3.12; 95% confidence interval, 1.37-7.14; P=0.007) were associated with IE (multivariate analysis including 3067 patients with individual data). The most frequent causal microorganisms were coagulase-negative staphylococci (24%), followed by Staphylococcus aureus (21%) and enterococci (21%). Vegetations were present in 77% of patients (transcatheter valve leaflets, 39%; stent frame, 17%; mitral valve, 21%). At least 1 complication of IE occurred in 87% of patients (heart failure in 68%). However, only 11% of patients underwent valve intervention (valve explantation and valve-in-valve procedure in 4 and 2 patients, respectively). The mortality rate in hospital was 47.2% and increased to 66% at the 1-year follow-up. IE complications such as heart failure (P=0.037) and septic shock (P=0.002) were associated with increased in-hospital mortality. CONCLUSIONS: The incidence of IE at 1 year after TAVI was 0.50%, and the risk increased with the use of orotracheal intubation and a self-expandable valve system. Staphylococci and enterococci were the most common agents. Although most patients presented at least 1 complication of IE, valve intervention was performed in a minority of patients, and nearly half of the patients died during the hospitalization period.

Clinical efficacy of percutaneous renal revascularization with stent placement in atherosclerotic renovascular disease.

OBJECTIVE: To evaluate the clinical efficacy of percutaneous renal revascularization with stenting to control hypertension and preserve/restore renal function in patients with atherosclerotic renovascular disease. METHODS: From May/1999 to October/2003, 46 patients with atherosclerotic renal artery stenosis (ARAS) underwent revascularization with stenting. The indication for the procedure was hypertension control and/or renal function preservation/restoration. Clinical characteristics: age range: 33-84 years (median = 58.5 +/-10.7), males: 26 (56.5%), 4 (10%) patients with diabetes mellitus, 21 (46%) patients with coronary artery disease, creatinine <2.0mg/dl: 39 (64%), 6 patients (14%) with congestive heart failure, 20 (43%) patients with ostial stenosis and 15 (33%) patients with bilateral stenosis. Hypertension control was evaluated by the number of drugs used before the procedure and at follow-up (FU) and by blood pressure (BP) measurement. RESULTS: The minimum follow-up was 7 months (range of 7-52, median: 23, mean: 24.2 +/- 15.2). There were no major complications. No patient experience any cardiovascular event. There was only one non-cadiac death (2%) and one technical failure in the treatment(2%). There was no serious complication in the procedure. None of the patients presented cardiovascular events. The renal function improved or stabilized in 32 patients (82%) and worsened in 4 (10%). The BP control improved in 19/44 (43,8%) patients and worsened / stabilized in 6 patients (14%). CONCLUSION: Angioplasty with renal artery stenting for ARAS showed to be an effective treatment strategy to restore and preserve renal function and to control blood pressure.

Uso da angiografia rotacional 3D (3D-RA) em portadores de cardiopatias congênitas: experiência de 53 casos / Use of 3D rotational angiography (3D-RA) in congenital heart disease: experience with 53 patients

Introdução: Os avanços no diagnóstico e tratamento das cardiopatias congênitas estão relacionados com os avanços na obtenção de imagens. As representações anatômicas obtidas com tomografia computadorizada, ressonância magnética e ecocardiografia têm ajudado, mas esses métodos não conseguem obter de forma precisa os dados hemodinâmicos. A angiografia rotacional 3D (3D-RA), um novo método de reconstrução tridimensional realizado no laboratório de cateterismo, tem sido amplamente utilizada em procedimentos neurológicos e urológicos. Nosso objetivo foi avaliar o desempenho da 3D-RA na avaliação das cardiopatias congênitas. Método: Revisão dos exames dos pacientes com cardiopatia congênita encaminhados para estudo hemodinâmico e que foram submetidos a aquisição de imagens pela 3D-RA. Foi utilizado equipamento Philips Allure FD10 e contraste de baixa osmolaridade para as angiografias. Resultados: No total, foram avaliados 53 pacientes, sendo utilizados, em média, 2,2 ± 1,1 ml/kg de contraste por paciente. Foi possível observar detalhes anatômicos não revelados em angiografias planares em 23% dos pacientes. Adicionalmente, 49% dos pacientes tiveram benefícios das imagens 3D para decisões terapêuticas. A exposição à radiação não foi estatisticamente diferente das angiografias planares. Nenhum paciente apresentou complicações relacionadas ao método. Conclusão: A 3D-RA forneceu informações que algumas das angiografias convencionais não fornecem e que ajudaram no tratamento de pacientes selecionados portadores de cardiopatia congênita. O emprego desse método poderá reduzir o número de aquisições de imagem por procedimento e, como consequência, limitar a exposição do paciente à radiação e ao contraste.

Background: Advances in the diagnosis and treatment of congenital heart disease are associated to advances in imaging techniques. Anatomic images obtained by computed tomography scan, magnetic resonance imaging (MRI) and echocardiography have been useful but cannot provide accurate hemodynamic data. 3D rotational angiography (3D-RA) is a new 3D reconstruction method carried out inthe cath lab that has been widely used in neurological and urological procedures. This study was aimed at evaluating the use of 3D-RA in the diagnosis and treatment of congenitalheart disease. Method: Review of catheterization results of patients with congenital heart disease referred for diagnostic assessment in which the 3D reconstruction method was employed. Philips Allure FD 10 equipment and low osmolarity contrast medium were used for angiographies. Results: Overall,53 patients were reviewed and 2.2 ± 1.1 mL/kg of contrast medium were used per patient. Anatomic details notpreviously shown by 2D angiographies were observed in 23% of the patients. Furthermore, 3D-RA imaging was usedto make treatment decisions in 49% of the patients. Exposure to radiation was not statistically different from 2D angiography. None of the patients had complications related to the method. Conclusion: 3D-RA provided information not usually seen by conventional angiography which was useful in thetreatment of selected patients with congenital heart disease. The use of 3D-RA may reduce the number of imaging tests per procedure and as a consequence, limit patient exposureto radiation and contrast media.

Eficácia clínica da revascularização renal percutânea com implante de stent em pacientes com doença renovascular aterosclerótica / Clinical efficacy of percutaneous renal revascularization with stent placement in atherosclerotic renovascular disease

OBJETIVO: Avaliar a eficácia da revascularização renal percutânea com implante de stent no controle da hipertensão e na preservação/restauração da função renal, em pacientes com doença renovascular aterosclerótica. MÉTODOS: De maio/1999 a outubro/2003, foram revascularizados 46 pacientes com estenose da artéria renal aterosclerótica (EAR-A), os quais foram submetidos ao implante de stent. A indicação para o procedimento foi controle da hipertensão e/ou preservação/restauração da função renal. Características gerais - Idade: 33-84 anos (mediana: 58,5±10,7), homens: 26 (56,5 por cento), diabéticos: 4 (10 por cento), DAC: 21 (46 por cento), creatinina < 2,0 mg/dl: 39 (64 por cento), ICC: 6 (14 por cento), estenoses ostiais 20 (43 por cento), estenose bilateral 15 (33 por cento). O controle da hipertensão foi averiguado pelo número de agentes utilizado antes do procedimento e durante o seguimento, e pela aferição da pressão arterial (PA). RESULTADOS: O seguimento mínimo foi de sete meses e variou de 7-52 (mediana: 23, média: 24,2±15,2). Houve apenas um óbito não-cardíaco (2 por cento) e uma falha técnica de tratamento (2 por cento). Não houve complicação grave do procedimento. Nenhum paciente apresentou evento cardiovascular. A função renal melhorou ou permaneceu inalterada em 32 (82 por cento) pacientes, e piorou em 4 (10 por cento). O controle da pressão arterial melhorou em 19/44 (43,8 por cento) dos pacientes e continuou descontrolada ou piorou em 6 (14 por cento). CONCLUSÃO: A angioplastia renal com implante de stent em pacientes com EAR demonstrou ser uma estratégia eficaz na recuperação e preservação da função renal e no controle da pressão arterial.

OBJECTIVE: To evaluate the clinical efficacy of percutaneous renal revascularization with stenting to control hypertension and preserve/restore renal function in patients with atherosclerotic renovascular disease. METHODS: From May/1999 to October/2003, 46 patients with atherosclerotic renal artery stenosis (ARAS) underwent revascularization with stenting. The indication for the procedure was hypertension control and/or renal function preservation/restoration. Clinical characteristics: age range: 33-84 years (median = 58.5 ±10.7), males: 26 (56.5 percent), 4 (10 percent) patients with dia betes mellitus, 21 (46 percent) patients with coronary artery disease, creatinine <2.0mg/dl: 39 (64 percent), 6 patients (14 percent) with congestive heart failure, 20 (43 percent) patients with ostial stenosis and 15 (33 percent) patients with bilateral stenosis. Hypertension control was evaluated by the number of drugs used before the procedure and at follow-up (FU) and by blood pressure (BP) measurement. RESULTS: The minimum follow-up was 7 months (range of 7-52, median: 23, mean: 24.2 ± 15.2). There were no major complications. No patient experience any cardiovascular event. There was only one non-cadiac death (2 percent) and one technical failure in the treatment(2 percent). There was no serious complication in the procedure. None of the patients presented cardiovascular events. The renal function improved or stabilized in 32 patients (82 percent) and worsened in 4 (10 percent). The BP control improved in 19/44 (43,8 percent) patients and worsened / stabilized in 6 patients (14 percent). CONCLUSION: Angioplasty with renal artery stenting for ARAS showed to be an effective treatment strategy to restore and preserve renal function and to control blood pressure.